[
  {
    "ts": null,
    "headline": "Tracking Chase Coleman's Tiger Global Portfolio - Q1 2025 Update",
    "summary": "Tracking Chase Coleman's Tiger Global Portfolio - Q1 2025 Update",
    "url": "https://finnhub.io/api/news?id=8217a9dbdb18eab5bb49b18cb25b3d9333ec2d370d12cfc46ea85bde2345c119",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749060979,
      "headline": "Tracking Chase Coleman's Tiger Global Portfolio - Q1 2025 Update",
      "id": 135024549,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8217a9dbdb18eab5bb49b18cb25b3d9333ec2d370d12cfc46ea85bde2345c119"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=86bdcbcf65276422d6848385690a99e783281a02db70fc3197872e6f05282c82",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749054660,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 135047472,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=86bdcbcf65276422d6848385690a99e783281a02db70fc3197872e6f05282c82"
    }
  },
  {
    "ts": null,
    "headline": "Lilly partners with Camurus in search of a long-lasting obesity drug",
    "summary": "The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help extend the durability of up to four of its weight-loss medicines.",
    "url": "https://finnhub.io/api/news?id=5378e2360480579a9d8c77eb753ca90fd6ba1891017f276ce325cb7a6e50b4a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749034860,
      "headline": "Lilly partners with Camurus in search of a long-lasting obesity drug",
      "id": 135011231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help extend the durability of up to four of its weight-loss medicines.",
      "url": "https://finnhub.io/api/news?id=5378e2360480579a9d8c77eb753ca90fd6ba1891017f276ce325cb7a6e50b4a4"
    }
  },
  {
    "ts": null,
    "headline": "Welldoc Says Working With Lilly To Launch Personalized Health & Medicine Platform",
    "summary": "Welldoc: * WELLDOC: WORKING WITH LILLY TO LAUNCH A NEW PERSONALIZEDHEALTH& MEDICINE PLATFORM FOR THOSE PRESCRIBED LILLY'S INCRETINTHERAPIESSource text:Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=b6bf77685e786d956bcba3f8fee75f685d50aa4b6294a45eb3c1000045a0a41e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749033008,
      "headline": "Welldoc Says Working With Lilly To Launch Personalized Health & Medicine Platform",
      "id": 135009824,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Welldoc: * WELLDOC: WORKING WITH LILLY TO LAUNCH A NEW PERSONALIZEDHEALTH& MEDICINE PLATFORM FOR THOSE PRESCRIBED LILLY'S INCRETINTHERAPIESSource text:Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=b6bf77685e786d956bcba3f8fee75f685d50aa4b6294a45eb3c1000045a0a41e"
    }
  },
  {
    "ts": null,
    "headline": "1 Underrated Reason to Buy This Market-Beating Stock",
    "summary": "Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication.  The company generates strong sales from products outside of diabetes and obesity care.  Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive.",
    "url": "https://finnhub.io/api/news?id=db48df7a17c18eaf4702eaa028f26078f83e5f2a1a041ce4d146f35eef17101c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749032100,
      "headline": "1 Underrated Reason to Buy This Market-Beating Stock",
      "id": 135010460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication.  The company generates strong sales from products outside of diabetes and obesity care.  Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive.",
      "url": "https://finnhub.io/api/news?id=db48df7a17c18eaf4702eaa028f26078f83e5f2a1a041ce4d146f35eef17101c"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027",
    "summary": "Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs.  Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion.  Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027.",
    "url": "https://finnhub.io/api/news?id=7f1823472143f5488bea7939d13ee2ac396a7485d2f183e5a2657415d6520c9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749028320,
      "headline": "Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027",
      "id": 135010789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs.  Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion.  Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027.",
      "url": "https://finnhub.io/api/news?id=7f1823472143f5488bea7939d13ee2ac396a7485d2f183e5a2657415d6520c9d"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Capital Appreciation Fund Q1 2025 Commentary",
    "summary": "During Q1 2025, the Harbor Capital Appreciation Fund returned -10.07%, underperforming its benchmark, the Russell 1000Â® Growth Index, which returned -9.97%.",
    "url": "https://finnhub.io/api/news?id=06e267cea6986ef2e057be41ba1f4220e07fcb639802fad91777e8785c9119e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749028020,
      "headline": "Harbor Capital Appreciation Fund Q1 2025 Commentary",
      "id": 135009115,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2142653674/image_2142653674.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "During Q1 2025, the Harbor Capital Appreciation Fund returned -10.07%, underperforming its benchmark, the Russell 1000Â® Growth Index, which returned -9.97%.",
      "url": "https://finnhub.io/api/news?id=06e267cea6986ef2e057be41ba1f4220e07fcb639802fad91777e8785c9119e2"
    }
  }
]